Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 16, 2006 Stephen D. Simpson	Lab Corp Doesn't Pass the Test Lab Corp may be a well-run company, but there just isn't enough room in the stock price.
The Motley Fool September 25, 2006 Brian Lawler	Merck's Positive Contribution Bad press from Vioxx shouldn't overshadow the company's new offering. Investors, take note.
The Motley Fool September 7, 2005 Stephen D. Simpson	The Little Lab That Could Bio-Reference is a small business with big potential. The company has an appealing cancer and genomics business (GenPath). For investors seeking successful yet unknown companies, this one is worth watching.
The Motley Fool October 24, 2006 Ryan Fuhrmann	Lab Corp's Healthy Prognosis: Fool by Numbers The lab-testing firm released fiscal third-quarter 2006 earnings: Here are the quick details investors need to know.
The Motley Fool July 20, 2007 Brian Lawler	Glaxo Heats Up the Vaccine Battle GlaxoSmithKline's cervical cancer vaccine gets a positive recommendation in the EU. Sales could begin in early 2008 and will compete with Gardasil, by rival Merck.
The Motley Fool October 19, 2009 Brian Orelli	The HPV Vaccine Wars of 2010 Merck and GlaxoSmithKline human papillomavirus vaccines were both approved by the Food and Drug Administration for different indications.
The Motley Fool October 7, 2005 Brian Gorman	Merck's Tricky Sell A vaccine for human papillomavirus clears scientific hurdles, but marketing could prove its biggest obstacle.
The Motley Fool July 7, 2009 Brian Orelli	Glaxo Missed the Boat The HPV vaccine market is declining before Glaxo can hop aboard.
The Motley Fool June 26, 2008 Brian Orelli	The FDA's Latest Victim Merck fails to get its Gardasil vaccine approved to treat older women.
The Motley Fool May 8, 2006 Stephen D. Simpson	Cytyc Looking Toward New Tech It's worth paying attention to this women's health company's transition to new growth drivers. Investors, take note.
BusinessWeek August 27, 2009 Arlene Weintraub	Is Merck Overselling a Cancer Vaccine? Fresh controversies are heating up over the marketing of products to prevent cervical cancer.
The Motley Fool April 4, 2007 Brian Lawler	GlaxoSmithKline Gets Ready for the Vaccine Wars British pharmaceutical powerhouse GlaxoSmithKline submits a marketing application to the FDA for its HPV vaccine. Investors, take note.
BusinessWeek November 29, 2004 Kerry Capell	"A Vaccine Every Woman Should Take" Two drug companies are closing in on shots against HPV, the leading cause of cervical cancer. Despite the obvious benefits, the vaccines may not be an easy sell: There are social and moral hurdles to overcome.
The Motley Fool February 8, 2007 Rich Duprey	Foolish Forecast: LabCorp Tests Positive The clinical lab-testing outfit is set to report its fourth-quarter 2006 earnings. Investors, here is what you can expect to see.
The Motley Fool November 3, 2010 Jeremy Phillips	Time to Sell Service Corp. International? Service Corp has failed three of the quick tests that would make it a sell.
Pharmaceutical Executive May 1, 2006 Joanna Breitstein	Cervical Cancer: Endagered Species Preventive care is more efficient than treating disease after the fact. Now this paradigm takes hold in cancer with new HPV vaccines. Now that the science is in order, Merck and GSK face several important challenges in conditioning the market.
The Motley Fool April 27, 2006 Stephen D. Simpson	Glaxo's Story Still Worth Reading A good pipeline could keep GlaxoSmithKline's already-impressive shares rolling.
The Motley Fool November 6, 2007 Brian Orelli	Getting Vaccinated Alongside Mom Merck presents data supporting use of its HPV vaccine in older women. The drugmaker may have a tough marketing job ahead of it.
The Motley Fool November 13, 2008 Brian Orelli	Merck Could Double Potential Customers Merck's HPV vaccine, Gardasil, which is now recommended for girls and women is also shown to benefit boys and men.
The Motley Fool April 12, 2007 Rich Duprey	Foolish Forecast: Checking UnitedHealth's Vitals The health services provider will report its first-quarter 2007 financial results shortly. Investors, here is what you can expect to see.
The Motley Fool January 31, 2006 Stephen D. Simpson	Merck Marking Time There won't be much good news for this pharmaceutical's investors until new products hit the market. If you already own Merck, you probably understand that patience will be the order of the day here.
The Motley Fool August 17, 2005 David Meier	The Power of Margins The way you think about margins can give you an investing edge.
BusinessWeek July 25, 2005 Catherine Arnst	O.K., Roll Up Your Sleeve New vaccines are arriving but the economics are still a challenge.
The Motley Fool August 31, 2006	Foolish Fundamentals: Margins Margins are important, but how you use margin information is more important to your investing success. Don't stay on the surface when analyzing margins. Your portfolio will thank you for it later.
The Motley Fool April 25, 2006 Stephen D. Simpson	Can Packaging Corp Break Out of the Box? Containerboard prices are on the way up, but the stocks aren't -- yet. Investors, Packaging Corp is worth a serious look.
The Motley Fool December 18, 2007 Brian Lawler	Cervarix Won't Save Glaxo Yet The FDA has another delay for this HPV vaccine. The agency has completed its review, but still has questions.
Pharmaceutical Executive May 1, 2006 Pasternak et al.	Vaccines: Market on the Rebound The vaccine business was safely inoculated against higher profits. But innovative therapies and looser government controls may spark an outbreak. Are pharmaceuticals ready for this opportunity?
The Motley Fool July 24, 2006 Stephen D. Simpson	Wait for a Bad Day at Merck Merck has value as a going concern, but investors should wait for some bad news to make the stock cheaper.
Health October 10, 2008	Cervical Cancer FAQ Signs, symptoms, prevention, and treatments are some of the topics explained here.
Information Today June 25, 2015	DynaMed Plus Gets Update EBSCO Health's DynaMed Plus added evidence-based content from Truven Health Analytics -- Micromedex Medication Management and Lab Recommendation resources.
The Motley Fool September 10, 2009 Brian Orelli	The Vanishing Vaccine War And it had such potential to be a bloodbath.
The Motley Fool July 25, 2007 Ryan Fuhrmann	The Latest Procedure From Quest Diagnostics Quest Diagnostics took a hit earlier this year from the loss of a major contract, but the lab testing firm isn't down for the count.
The Motley Fool January 31, 2007 Brian Gorman	Merck's Special Interest Merck is likely to succeed in getting states to mandate HPV vaccination. Still, investors shouldn't necessarily bet everything on Gardasil.
Insurance & Technology April 2, 2008 Nathan Conz	The Hartford's Innovation Lab Unveils LIFT Initiative The Hartford's Innovation Lab, headed by John Anthony, is piloting LIFT, a telematics-based research project aimed at finding the causes of repetitive back injuries common in its workers compensation business.
The Motley Fool June 9, 2005 Richard Gibbons	Buying on Margins Profit margins are one useful tool for finding great stock values.
The Motley Fool January 19, 2006 Stephen D. Simpson	UnitedHealth Staying Fit Let the analysts chirp about the quarter; this remains an exceptionally well-run company. Investors, take note.
The Motley Fool December 9, 2011 Paul Chi	3 Europe-Proof Stocks for Your Portfolio These health-care stocks are Europe-proof.
The Motley Fool April 7, 2005 Brian Gorman	Merck Soldiers On The drug company's experimental HPV treatment has significant potential. Investors should not overlook the company's positive developments.
Bank Technology News February 2010 Karen Epper Hoffman	Banks Incubate The Innovation Fixation Most banks don't have Apple-esque credentials when it comes to innovation, but more are not only seeing the value of thinking out the box, but also understanding that creativity doesn't happen in isolation-hence the innovation lab.
Scientific American November 2008 Jessica Wapner	Cancer Vaccine: Looking Beyond Tumor Size Proponents see hope in changing cancer vaccines' bad reputation
The Motley Fool October 11, 2010 Travis Hoium	GNBT Shares Popped Then Plunged: What You Need to Know Generex Biotechnology Corp shares rose 25% in early market trading before falling on news the company will acquire a 51% stake in Global Medical Direct.
Scientific American February 2006	To Banish a Cancer Two vaccines that are nearing approval by the Food and Drug Administration in the U.S. have demonstrated in clinical trials that they can prevent infection from the two types of the human papillomavirus (HPV) that account for up to 70 percent of cervical cancers.
Managed Care September 2006 Thomas Morrow	Remarkable Work Went Into Designing the New HPV Vaccine The recently approved human papillomavirus vaccine is a prime example of how science is beating back the advance of old diseases.
The Motley Fool June 26, 2008 Brian Lawler	Gauging Glaxo's Vaccine Value Surprise! The FDA actually approves Glaxo's new combination children's vaccine without delay.
HHMI Bulletin Fall 2012 Robert Tjian	President's Letter: Stabilizing Forces Recognizing the role of research professionals in today's laboratory organizations is important not only to the individuals who contribute their services but also to the research enterprise as a whole.
Information Today September 24, 2013	Labguru Launches Mobile App for Scientists Life science researchers who are on-the-go can now plan, record, and share lab information with colleagues while they are away from their lab benches.
Pharmaceutical Executive July 3, 2007 Jill Wechsler	Washington Report: Vaccines for Everyone New vaccines can be good business and a huge boon to public health. But the challenge is to establish prices that ensure global access, and to bring necessary medications to third-world countries.
The Motley Fool October 22, 2007 Billy Fisher	An Unwavering Approach at UnitedHealth Group UnitedHealth Group repurchases $2 billion of shares during Q3. Their disciplined pricing approach has enabled the company to consistently improve operating margins.
National Defense August 2011 Eric Beidel	New Army Lab Troubleshoots Radios Before Field Tests A recent version of the Army's Joint Tactical Radio System failed so often during tests last year that troops had to relay messages on foot.
The Motley Fool January 24, 2007 Rich Duprey	EZ Corp on Easy Street: Fool by Numbers The payday lender released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...